Lineage Cell Therapeutics (LCTX) said Tuesday it started a clinical study evaluating OPC1, an investigational allogeneic stem cell-derived transplant for spinal cord injury.
OPC1 is designed to replace or support spinal cord cells that are absent or dysfunctional due to traumatic injury, aiming to restore or enhance functional activity in affected individuals, the company said.
The company said the study will assess the safety and utility of the Manual Inject Parenchymal Spinal Delivery System, a novel device developed to deliver OPC1 directly to the injury site.
It will enroll both subacute patients, treated between 21 and 42 days after injury, and chronic spinal cord injury patients, treated between one and five years after injury, according to the company.
Shares of Lineage Cell Therapeutics were down more than 2% in recent trading.
Price: 0.64, Change: -0.02, Percent Change: -2.29
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。